Metagenomi Therapeutics, Inc. MGX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026
Metagenomi Therapeutics, Inc. (MGX) is a healthcare company listed in the US with a market value of about $26M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$94M, a net margin of -1329.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -39%.
About Metagenomi Therapeutics
Metagenomi Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 375% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $7M | $25M | $52M | $45M |
| Net income | -$94M | -$88M | -$78M | -$68M |
| Free cash flow | -$84M | -$89M | -$112M | -$101M |
| EPS (diluted) | $-2.50 | $-2.36 | $-2.36 | $-20.05 |
| Net margin | -1329.3% | -348.5% | -149.3% | -152.5% |
| ROIC | — | -48.1% | -29.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Metagenomi Therapeutics pay a dividend?
Not currently.
Is Metagenomi Therapeutics a good stock to buy?
We do not give buy or sell advice. Metagenomi Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.